Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “buy” rating reiterated by equities research analysts at William Blair in a research report issued on Thursday. William Blair also issued estimates for Spark Therapeutics’ Q1 2018 earnings at $1.20 EPS, Q2 2018 earnings at ($1.41) EPS, FY2018 earnings at ($2.30) EPS, FY2019 earnings at ($4.20) EPS, FY2020 earnings at ($5.02) EPS, FY2021 earnings at ($5.03) EPS and FY2022 earnings at ($4.26) EPS.
Other research analysts have also issued reports about the company. Mizuho started coverage on Spark Therapeutics in a research report on Monday, February 12th. They set a “buy” rating and a $79.00 price target for the company. SunTrust Banks raised their price target on Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a research report on Thursday, January 4th. Raymond James set a $66.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $105.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, BMO Capital Markets set a $67.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $70.58.
ONCE opened at $81.39 on Thursday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The firm has a market cap of $3,031.36, a PE ratio of -10.67 and a beta of 2.56.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, hitting the consensus estimate of ($1.73). Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. The business had revenue of $7.41 million during the quarter, compared to analyst estimates of $9.53 million. equities research analysts predict that Spark Therapeutics will post -3.33 EPS for the current year.
In other news, COO John Furey sold 13,277 shares of the stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $82.52, for a total value of $1,095,618.04. Following the sale, the chief operating officer now directly owns 2,277 shares in the company, valued at $187,898.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ONCE. Gilder Gagnon Howe & Co. LLC acquired a new stake in Spark Therapeutics in the fourth quarter valued at $28,188,000. Rockefeller Financial Services Inc. raised its stake in Spark Therapeutics by 27,905.0% in the fourth quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock valued at $18,202,000 after buying an additional 352,719 shares in the last quarter. OppenheimerFunds Inc. acquired a new stake in Spark Therapeutics in the fourth quarter valued at $11,249,000. Macquarie Group Ltd. acquired a new stake in Spark Therapeutics in the fourth quarter valued at $9,012,000. Finally, Spark Investment Management LLC acquired a new stake in Spark Therapeutics in the fourth quarter valued at $8,833,000.
ILLEGAL ACTIVITY NOTICE: “William Blair Reiterates “Buy” Rating for Spark Therapeutics (ONCE)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2018/04/21/william-blair-reiterates-buy-rating-for-spark-therapeutics-once.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.